IAS SEVERE FH PANEL

IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”

The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.

To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.

Other FH activities

LAUNCH E-LEARNING

Improving management through genetic testing for Familial Hypercholesterolaemia (FH)

This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:

• Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
• How and why to use genetic testing
• How to interpret results
• How to use cascade screening to identify related individuals at risk

FIRST DYSLIPIDEMIA and FH CLINIC in IRAQ

The establishment of the first dyslipidemia and FH clinic in Iraq by Dr. Mutaz Al-Sabah – a research, diagnostic and therapeutic center at the Al-Diwaniyah teaching hospital which will ultimately separate the FH clinic in the future as an independent center dealing with familial lipid disorders. Dr. Al-Sabah has also attended the first IAS-OSLA course on Lipid Metabolism and Cardiovascular Risk held in Muscat-Oman in February 2015 and has been a very active member of the IAS-OSLA Community since then.

The SAFEHEART Registry

Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.

The International Atherosclerosis Society (IAS) and the Oman Society of Lipid and Atherosclerosis (OSLA) are happy to make available to our readers some important documents related to the 3rd IAS – OSLA Course on Lipid Metabolism and Cardiovascular Risk which was held in Muscat, Oman (February 25-27, 2017) and co-chaired by Profs. Yuji Matsuzawa and Philip Barter of the International Atherosclerosis Society and Dr. Khalid Al-Rasadi, President of the Oman Society of Lipid and Atherosclerosis.

• Complete Report
• Scientific Program
• Faculty and Participants Photo
• Slide Library of the Course is posted at: http://www.athero.org/slidelibrary.asp